• My research focus is on understanding the molecular basis of cancer using integrative genomic, epigenetic and proteomic approach. Our groups translational cancer research involves transferring the basic research discoveries to develop disease detection markers of developing therapy for the identified targets. I have worked extensively in the area of solid tumor genomics, biomarker discovery, biology, and therapeutic targeting.
    Our group’s research helps better understand the molecular alterations during the initiation and progression of multiple human malignancies. We perform integrative analysis to identify the best targets and work towards developing agents/drugs for specific causative targets. We would like to develop multiple collaborations in order to hasten the pace of cancer research and discovery by team science approach. In order to enhance the cancer research/target discovery, we built a discovery platform called UALCAN (http://ualcan.path.uab.edu) for cancer genomic and proteomic data analysis, making cancer research a worldwide team effort. This portal has been visited over a "Million" times and cited over 3,500 times from researchers across the globe since its release in 2017. Some of the candidate therapeutic targets that I have identified include Histone Methyltransferase EZH2, AMACR, TPD52, MTA1, ERG gene fusion, SPINK1, CtBP1, RAF kinase gene fusions, GOLM1, GLYATL1 and JAGGED1 in prostate cancer, GATA3, AGTR1, EZH2, CCN6 (WISP3) in breast cancer and MTHFD1L, PAICS and PAK4 in bladder cancer among others. I have patents for targeting histone methyltransferase EZH2 and MMSET.
    My research has resulted in prolific output of publications and currently I am part of over 145 published articles and many of them in high impact factor (IF), prestigious journals including Science, Nature, New England Journal of Medicine, Nature Medicine, Cancer Cell, Cancer Discovery, Blood, PNAS, Cancer Research, Oncogene among others. Our research has been highly cited and our work has been cited by leading cancer researchers and biologists worldwide with over 41,500 citations with an h-Index of 72. I was part of the team that won the Inaugural American Association for Cancer Research (AACR) Team Science Award for this discovery in 2007.
    I am actively involved in teaching and Co-Director of the Cancer Biology Theme of UAB-Graduate Biomedical Sciences (GBS). I also direct the GBS-728, Cancer Genomics, Epigenetics and Therapy, as the director of this course. This course is designed to educate the students on the basic and novel concepts to understand cancer. I also organize the Translational Research Group Meeting, a tri-Departmental interactive seminar series.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Author Correction: Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways (Nature Communications, (2022), 13, 1, (2669), 10.1038/s41467-022-30342-3)Nature Communications.  13. 2022
    2022 Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathwaysNature Communications.  13. 2022
    2022 Developing 3D Organoid Raft Cultures from Patient-Derived Xenografts as Rapid Models to Screen Efficacy of Experimental TherapeuticsInternational Journal of Molecular Sciences.  23. 2022
    2022 ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsJCI Insight.  7. 2022
    2022 Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast CancersCancers.  14. 2022
    2022 Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemicBMJ Open.  12. 2022
    2022 DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancerMolecular Oncology.  16:1728-1745. 2022
    2022 UALCAN: An update to the integrated cancer data analysis platformNeoplasia.  25:18-27. 2022
    2022 MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosisBlood.  139:761-778. 2022
    2022 Global molecular alterations involving recurrence or progression of pediatric brain tumorsNeoplasia.  24:22-33. 2022
    2021 Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cellsScientific Reports.  11. 2021
    2021 The TGF-β/HDAC7 axis suppresses TCA cycle metabolism in renal cancerJCI Insight.  6. 2021
    2021 Corrigendum to ‘Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model’ [Translational Oncology 13 (2020) 100754] (Translational Oncology (2020) 13(4), (S1936523320301030), (10.1016/j.tranon.2020.100754))Translational Oncology.  14. 2021
    2021 NAB2-STAT6 Gene Fusions to Evaluate Primary/Metastasis of Hemangiopericytoma/Solitary Fibrous TumorsAmerican Journal of Clinical Pathology.  156:906-912. 2021
    2021 Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancerFrontiers in Bioscience-Landmark.  26:765-776. 2021
    2021 Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinomaTranslational Oncology.  14. 2021
    2021 Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian WomenTranslational Oncology.  14. 2021
    2021 Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancersOncogene.  40:2081-2095. 2021
    2021 Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypesBreast Cancer.  28:496-505. 2021
    2021 TGF-β signaling suppresses TCA cycle metabolism in renal cancer 2021
    2021 Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic. 2021
    2021 ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition 2021
    2020 EZH2-targeted therapies in cancer: Hype or a realityCancer Research.  80:5449-5458. 2020
    2020 TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability statusMolecular Oncology.  14:3007-3029. 2020
    2020 MicroRNA-mediated inflammation and coagulation effects in rats exposed to an inhaled analog of sulfur mustardAnnals of the New York Academy of Sciences.  1479:148-158. 2020
    2020 Re: Therapeutically Actionable PAK4 is Amplified, Overexpressed, and Involved in Bladder Cancer ProgressionInvestigative urology.  204:622-623. 2020
    2020 PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its ProgressionTranslational Oncology.  13. 2020
    2020 PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expressionMatrix Biology.  89:43-58. 2020
    2020 Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells 2020
    2020 Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancerPLoS One.  15. 2020
    2020 PRDM16 suppresses HIF-targeted gene expression in kidney cancerJournal of Experimental Medicine.  217. 2020
    2020 Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progressionOncogene.  39:4077-4091. 2020
    2020 Fermentable fibers induce rapid macro- And micronutrient depletion in Toll-like receptor 5-deficient mice 2020
    2020 Dynamic Regulation of TET2 by Phosphorylation and Dephosphorylation at Ser99 2020
    2020 PAICS, a purine nucleotide metabolic enzyme, is involved in tumor growth and the metastasis of colorectal cancerCancers.  12. 2020
    2020 Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX ModelTranslational Oncology.  13. 2020
    2020 Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunitiesCancer Letters.  470:134-140. 2020
    2020 14-3-3 proteins protect AMPK-phosphorylated ten-eleven translocation-2 (TET2) from PP2A-mediated dephosphorylationJournal of Biological Chemistry.  295:1754-1766. 2020
    2019 Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancersNature Communications.  10. 2019
    2019 Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder CancerTranslational Oncology.  12:1416-1424. 2019
    2019 MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal CancerTranslational Oncology.  12:1461-1467. 2019
    2019 Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer 2019
    2019 Pseudogene Associated Recurrent Gene Fusion in Prostate CancerNeoplasia.  21:989-1002. 2019
    2019 Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression 2019
    2019 Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer 2019
    2019 Abstract 851: MicroRNA-124 modulated collagen-prolyl hydroxylase P4HA1 expression regulates colon cancer progressionCancer Research.  79:851-851. 2019
    2019 Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survivalCancer.  125:921-932. 2019
    2019 Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancerOncoImmunology.  8. 2019
    2019 Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failureLaboratory Investigation.  99:371-386. 2019
    2019 Molecular correlates of metastasis by systematic pan-cancer analysis across the cancer genome atlasMolecular Cancer Research.  17:476-487. 2019
    2019 The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtypePLoS One.  14. 2019
    2019 Ferritin light chain confers protection against sepsis-induced inflammation and organ injuryFrontiers in Immunology.  10. 2019
    2019 Integrative epigenetic and gene expression analysis of renal tumor progression to metastasisMolecular Cancer Research.  17:84-96. 2019
    2018 Wnt receptor Frizzled 8 is a target of ERG in prostate cancer 2018
    2018 The PTEN Mutation in Cowden Syndrome: A Case ReportAmerican Journal of Gastroenterology.  113:s846-s847. 2018
    2018 A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer ProgressionNeoplasia.  20:894-904. 2018
    2018 Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic TargetsEuropean urology focus.  4:733-736. 2018
    2018 Abstract 4483: Functional implications of PRDM16 loss in kidney cancerCancer Research.  78:4483-4483. 2018
    2018 miR-34a regulates expression of the stathmin-1 oncoprotein and prostate cancer progressionMolecular Cancer Research.  16:1125-1137. 2018
    2018 214 High fat diet accelerates UVB-induced development of basal cell and squamous cell carcinoma in Ptch+/-/SKH-1 miceJournal of Investigative Dermatology.  138:s36. 2018
    2018 Histone methyltransferase ezh2: A therapeutic target for ovarian cancerMolecular Cancer Therapeutics.  17:591-602. 2018
    2018 Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behaviorMatrix Biology.  65:104-118. 2018
    2017 Prostate Cancer: An Update on Molecular Pathology with Clinical ImplicationsEuropean Urology Supplements.  16:253-271. 2017
    2017 Prostate cancer imaging and biomarkers guiding safe selection of active surveillanceFrontiers in Oncology.  7. 2017
    2017 UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival AnalysesNeoplasia.  19:649-658. 2017
    2017 Erratum: Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer (Cancer Cell (2017) 31(4) (532–548.e7)(S1535610817300600)(10.1016/j.ccell.2017.02.017))Cancer Cell.  31:844-847. 2017
    2017 Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate CancerCancer Cell.  31:532-548.e7. 2017
    2017 Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cellsScientific Reports.  7. 2017
    2017 Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma 2017
    2017 Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer 2017
    2016 MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancerOncogene.  35:6330-6340. 2016
    2016 Genomic and Epigenomic Alterations in CancerAmerican Journal of Pathology.  186:1724-1735. 2016
    2016 Divergent clonal evolution of castration-resistant neuroendocrine prostate cancerNature Medicine.  22:298-305. 2016
    2016 Erratum: TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer (Nature Communications (2014) 5 (4527) DOI: 10.1038/ncomms5527)Nature Communications.  7. 2016
    2016 Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. 2016
    2016 Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restrictionNature Immunology.  17:95-103. 2016
    2015 Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinomaCell Cycle.  14:2798-2809. 2015
    2015 Cancer: The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signalingScience Signaling.  8. 2015
    2015 Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancerOncotarget.  6:23445-23461. 2015
    2014 TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancerNature Communications.  5. 2014
    2014 The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progressionOncotarget.  5:6654-6669. 2014
    2013 Targeting the link between late pregnancy and breast cancereLife.  2013. 2013
    2013 Prostate cancer genomics: Progress and promiseEuropean Urology.  64:577-578. 2013
    2013 Erratum: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression (Nature (2009) 457 (910-914) DOI: 10.1038/nature07762)Nature.  499:504. 2013
    2013 Erratum to Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer [Cancer Cell, 19 (2011) 664-678]Cancer Cell.  23:557. 2013
    2013 Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in CancerMolecular Cell.  49:80-93. 2013
    2012 The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells.Journal of Biological Chemistry.  287:43862-43875. 2012
    2012 Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models 2012
    2012 Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cellsBlood.  119:1274-1282. 2012
    2012 Role of transcriptional corepressor CtBP1 in prostate cancer progressionNeoplasia.  14:905-914. 2012
    2011 The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinomaOncogene.  30:4339-4349. 2011
    2011 TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancersCancer Research.  71:5387-5392. 2011
    2011 Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortalityBlood.  117:6172-6183. 2011
    2011 Characterization of KRAS rearrangements in metastatic prostate cancerCancer Discovery.  1:35-43. 2011
    2011 Therapeutic targeting of SPINK1-positive prostate cancerScience Translational Medicine.  3. 2011
    2011 Coordinated Regulation of Polycomb Group Complexes through microRNAs in CancerCancer Cell.  20:187-199. 2011
    2011 Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate CancerCancer Cell.  19:664-678. 2011
    2010 The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancerOncogene.  29:5370-5380. 2010
    2010 Letter to the editorEuropean Urology.  58. 2010
    2010 Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaNature Medicine.  16:793-798. 2010
    2010 An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer ProgressionCancer Cell.  17:443-454. 2010
    2010 Antibody-based detection of ERG rearrangement-positive prostate cancerNeoplasia.  12:590-598. 2010
    2010 Chlorpromazine induced cataract in a young patient with schizophrenia.Indian Journal of Psychological Medicine.  32:69-70. 2010
    2009 Induced chromosomal proximity and gene fusions in prostate cancerScience.  326:1230. 2009
    2009 An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancerNature Biotechnology.  27:1005-1011. 2009
    2009 Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetasesPLoS One.  4. 2009
    2009 AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist 2009
    2009 Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature.  457:910-914. 2009
    2009 Tomlins et al. replyNature.  457. 2009
    2009 RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer diseaseNeoplasia.  11:956-963. 2009
    2008 Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancerScience.  322:1695-1699. 2008
    2008 Repression of E-cadherin by the polycomb group protein EZH2 in cancerOncogene.  27:7274-7284. 2008
    2008 A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: Identification of DDX5-ETV4 fusion protein in prostate cancerCancer Research.  68:7629-7637. 2008
    2008 The Role of SPINK1 in ETS Rearrangement-Negative Prostate CancersCancer Cell.  13:519-528. 2008
    2008 Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancerCancer Research.  68:73-80. 2008
    2008 Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancerNeoplasia.  10:1285-1294. 2008
    2008 Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1American Journal of Pathology.  172:893-904. 2008
    2008 Role of the TMPRSS2-ERG gene fusion in prostate cancerNeoplasia.  10:177-188. 2008
    2007 Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition 2007
    2007 A polycomb repression signature in metastatic prostate cancer predicts cancer outcomeCancer Research.  67:10657-10663. 2007
    2007 Integrative Genomics Analysis Reveals Silencing of β-Adrenergic Signaling by Polycomb in Prostate CancerCancer Cell.  12:419-431. 2007
    2007 Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancerNature.  448:595-599. 2007
    2007 Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicityOncogene.  26:3431-3439. 2007
    2007 Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivoClinical Cancer Research.  13:2512-2518. 2007
    2007 Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinomaCancer Research.  67:3461-3467. 2007
    2007 Molecular concepts analysis links tumors, pathways, mechanisms, and drugsNeoplasia.  9:443-454. 2007
    2007 Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profilesNeoplasia.  9:166-180. 2007
    2006 Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiationCancer Research.  66:11554-11559. 2006
    2006 Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2′,5′-oligoadenylate synthetase from prostate cancer cellsNucleic Acids Research.  34:6684-6695. 2006
    2006 Differential proteomic alterations between localised and metastatic prostate cancerBritish Journal of Cancer.  95:425-430. 2006
    2006 A systems approach to model metastatic progressionCancer Research.  66:5537-5539. 2006
    2006 Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibitionInternational Journal of Cancer.  118:1041-1050. 2006
    2006 Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivoJournal of Experimental Medicine.  203:203-213. 2006
    2006 ADAM15 disintegrin is associated with aggressive prostate and breast cancer diseaseNeoplasia.  8:319-329. 2006
    2006 Defining aggressive prostate cancer using a 12-gene modelNeoplasia.  8:59-68. 2006
    2005 Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysisCancer Research.  65:11259-11264. 2005
    2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancerScience.  310:644-648. 2005
    2005 Autoantibody signatures in prostate cancerNew England Journal of Medicine.  353:1224-1235. 2005
    2005 Probabilistic model of the human protein-protein interaction networkNature Biotechnology.  23:951-959. 2005
    2005 The unfolded protein response modulates toxicity of the expanded glutamine androgen receptorJournal of Biological Chemistry.  280:21264-21271. 2005
    2005 α-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysisCancer Epidemiology, Biomarkers and Prevention.  14:1418-1423. 2005
    2005 Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)Cancer Research.  65:3328-3335. 2005
    2005 Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progressionCancer Cell.  8:393-406. 2005
    2005 The polycomb group protein EZH2 impairs DNA repair in breast epithelial cellsNeoplasia.  7:1011-1019. 2005
    2004 Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy programCancer Research.  64:9209-9216. 2004
    2004 JAGGED1 expression is associated with prostate cancer metastasis and recurrenceCancer Research.  64:6854-6857. 2004
    2004 Natural antibodies sustain differentiation and maturation of human dendritic cells 2004
    2004 Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Rubin, MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer, MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM, Department of Pathology, Brigham and Women's Hospital, Boston, MA. Cancer Res 2004;64:3814–22Urologic Oncology: seminars and original investigations.  22:436-437. 2004
    2004 Overexpression, amplification, and androgen regulation of TPD52 in prostate cancerCancer Research.  64:3814-3822. 2004
    2004 Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cellsInternational Immunology.  16:517-524. 2004
    2004 The Role of Metastasis-Associated Protein 1 in Prostate Cancer ProgressionCancer Research.  64:825-829. 2004
    2004 C5a-Induced Gene Expression in Human Umbilical Vein Endothelial CellsAmerican Journal of Pathology.  164:849-859. 2004
    2003 EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells 2003
    2002 Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimensAmerican Journal of Pathology.  161:1743-1748. 2002
    2002 The polycomb group protein EZH2 is involved in progression of prostate cancerNature.  419:624-629. 2002
    2002 Autoantibodies to heat shock protein 90 in the human natural antibody repertoire.International Immunology.  14:453-461. 2002
    2002 α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancerJournal of the American Medical Association.  287:1662-1670. 2002
    2002 Molecular cross-talk between the TRAIL and interferon signaling pathwaysJournal of Biological Chemistry.  277:575-585. 2002
    2002 α-Methylacyl-CoA racemase: Expression levels of this novel cancer biomarker depend on tumor differentiationAmerican Journal of Pathology.  161:841-848. 2002
    2001 Profiling of cancer cells using protein microarrays: Discovery of novel radiation-regulated proteinsCancer Research.  61:7585-7593. 2001
    2001 Delineation of prognostic biomarkers in prostate cancerNature.  412:822-826. 2001
    2001 Variable sensitivity of lymphoblastoid cells to apoptosis induced by Viscum album Qu FrF, a therapeutic preparation of mistletoe lectin. 2001
    2000 Natural antibodies to factor VIII.Seminars in vascular medicine.  26:157-165. 2000
    1999 Catalytic activity of antibodies against factor VIII in patients with hemophilia A.Nature Medicine.  5:1044-1047. 1999
    1998 Refolding of native and recombinant chicken riboflavin carrier (or binding) protein: evidence for the formation of non-native intermediates during the generation of active protein. 1998
    1998 Identification and characterization of receptors for riboflavin carrier protein in the chicken oocyte. Role of the phosphopeptide in mediating receptor interaction. 1998
    1996 Hyperexpression of chicken riboflavin carrier protein: antibodies to the recombinant protein curtail pregnancy in rodents.Protein Expression and Purification.  7:147-154. 1996

    Research Overview

  • Cancer Genomics, Epigenetics, Proteomics, Signal Transduction, Bioinformatics, Cancer Biology and Target Discovery. Therapeutic Targeting. Cancer data analysis and dissemination to cancer researchers through UALCAN web portal (http://ualcan.path.uab.edu)
  • Investigator On

  • 3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama Ca Ctr Partnership - Research Projects  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse Sch of Medicine/Tuskegee Univ/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership - Biostatistics/Bioinformatics  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS
  • Blocking Arsenicals-Induced Cutaneous Injury  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Characterization of SEMA5B Mediated Oncogenic Signaling in Renal Cell Carcinoma  awarded by American Urological Association
  • Chemoprevention of Environmental UVB-Induced Skin Cancer in Immunosuppressed Mice  awarded by National Institute of Environmental Health Sciences/NIH/DHHS
  • Mononuclear Phagocytes in the Pathogenesis of Acute Kidney Injury  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Regulation of the Kidney Cancer Epigenome by Oncometabolite L-2-Hydroxyglutarate  awarded by National Cancer Institute/NIH/DHHS
  • UAB Research Center of Excellence in Arsenicals  awarded by National Institute of Environmental Health Sciences/NIH/DHHS
  • Education And Training

  • Hôpital Broussais, INSERM Unit, Postdoctoral Research
  • University Of Michigan Pathology, Postdoctoral Research
  • Master of Business Administration in Marketing, University of Alabama at Birmingham 2022
  • Doctor of Philosophy in Biochemistry, Indian Institute of Science 1997
  • Master of Science in Biochemistry, Manipal University 1991
  • Bachelor of Science or Mathematics in Chemistry, Mangalore University 1989
  • Full Name

  • Sooryanarayana Varambally